October 28, 2022 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

The Committee will discuss biologics license application 761176 for 131I-omburtumab solution for injection, submitted by Y-mAbs Therapeutics, Inc. for the proposed indication of treatment of neuroblastoma with central nervous system/leptomeningeal metastases. Meeting Information and Materials: https://www.fda.gov/advisory-committe...